Boston Scientific grows strongly in the first quarter of 2025
Boston Scientific Corporation $B1SX34 presented impressive figures in the first quarter of 2025. With sales of 4.663 billion euros, the company achieved growth of 20.9% compared to the previous year. Earnings per share (EPS) also showed a positive development, climbing to EUR 0.45 compared to EUR 0.33 in the previous year. Particularly noteworthy is the adjusted EPS of EUR 0.75, which represents a significant improvement compared to EUR 0.56 in the previous year. CEO Mike Mahoney emphasized the company's impressive product portfolio and innovative strength. All business areas recorded growth, with the Cardiovascular segment standing out in particular at 26.2 %. An increase of 11.7 % was also achieved in the MedSurg segment. In the USA, sales even grew by 31.1 %. With new clinical studies, the company aims to further advance its innovation strategy and evaluate the safety and efficacy of its products.
AT&T impresses with solid quarterly figures
In the USA, AT&T Inc. $T (+0.73%) also presented strong results in the first quarter of 2025. Revenue rose to 30.6 billion euros, an increase of 2% compared to the same quarter of the previous year. Earnings per share amounted to EUR 0.61, compared to EUR 0.47 in the previous year. The adjusted EPS of 0.51 euros shows a slight improvement compared to the previous year. Particularly pleasing is the announcement of 324,000 new postpaid telephone customers that the company was able to acquire in this quarter. Revenue from mobility services amounted to EUR 16.7 billion, which corresponds to a year-on-year increase of 4.1%. AT&T is optimistic for the full year 2025 and expects consolidated services to grow in the low single digits. The company is also planning capital investments of around EUR 22 billion and is considering share buybacks in the second quarter. Another focus is on the planned sale of its 70% stake in DIRECTV, which is scheduled for mid-2025.
Sources: